|Dr. Richard Sachse M.D., Ph.D.||Sr. VP, CSO & Chief Medical Officer||277.5k||N/A||N/A|
|Mr. Michael V. Ward||Chief Exec. Officer||N/A||N/A||60|
|Mr. Paul Burroughs||Director of Communications||N/A||N/A||N/A|
|Dr. Eckhard G. Guenther Ph.D.||VP of Alliance Management||N/A||N/A||N/A|
|Dr. Michael Teifel Ph.D.||VP of Non-Clinical Sciences||N/A||N/A||N/A|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.